Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Duloxetine-associated tardive dyskinesia resolved with fluvoxamine: a case report.

× No keyword cloud information.

9 in total

1. Beneficial Effects of Fluvoxamine for Chorea in a Patient With Huntington's Disease: A Case Report.

Authors: Yakup Albayrak; Görkem Karakas Uğurlu; Mustafa Uğurlu; Ali Cayköylü
Journal: Prim Care Companion CNS Disord Date: 2012

2. Drug-induced movement disorder and confusion associated with duloxetine.

Authors: Sarah Hasan Siddiqui; Nadeem Ahmed Memon; Ravi Shanker
Journal: BMJ Case Rep Date: 2018-03-28

3. Beneficial effects of the sigma-1 agonist fluvoxamine for tardive dyskinesia in patients with postpsychotic depressive disorder of schizophrenia: report of 5 cases.

Authors: Yakup Albayrak; Kenji Hashimoto
Journal: Prim Care Companion CNS Disord Date: 2012-11-08

4. Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials.

Authors: Taro Kishi; Tomoya Hirota; Nakao Iwata
Journal: Eur Arch Psychiatry Clin Neurosci Date: 2013-04-21 Impact factor: 5.270

5. An update on tardive dyskinesia: from phenomenology to treatment.

Authors: Olga Waln; Joseph Jankovic
Journal: Tremor Other Hyperkinet Mov (N Y) Date: 2013-07-12

Review 6. Tardive Dyskinesia-like Syndrome Due to Drugs that do not Block Dopamine Receptors: Rare or Non-existent: Literature Review.

Authors: Anelyssa D'Abreu; Joseph H Friedman
Journal: Tremor Other Hyperkinet Mov (N Y) Date: 2018-08-31

7. A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine.

Authors: Yakup Albayrak; Murat Beyazyüz; Özlem Abbak; Ece Altındağ
Journal: Clin Psychopharmacol Neurosci Date: 2019-02-28 Impact factor: 2.582

8. Benefical effects of sigma-1 agonist fluvoxamine for tardive dyskinesia and tardive akathisia in patients with schizophrenia: report of three cases.

Authors: Yakup Albayrak; Kenji Hashimoto
Journal: Psychiatry Investig Date: 2013-10-24 Impact factor: 2.505

9. (+)-9-Trifluoroethoxy-α-Dihydrotetrabenazine as a Highly Potent Vesicular Monoamine Transporter 2 Inhibitor for Tardive Dyskinesia.

Authors: Wenyan Wang; Guangying Du; Shilan Lin; Jing Liu; Huijie Yang; Dawei Yu; Liang Ye; Fangxia Zou; Hongbo Wang; Rui Zhang; Jingwei Tian
Journal: Front Pharmacol Date: 2021-12-07 Impact factor: 5.810

9 in total